| Dr Nicholas Paul Marburger, DO | |
|
601 E Rollins St, Orlando, FL 32803-1248 | |
| (407) 303-5600 | |
| Not Available |
| Full Name | Dr Nicholas Paul Marburger |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 7 Years |
| Location | 601 E Rollins St, Orlando, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043741044 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | OS16785 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bayfront Health - St Petersburg | Saint petersburg, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Physicians Of Crossroads | 2264894245 | 14 |
News Archive
The European Society of Human Reproduction and Embryology is setting the first ever standards in Cross Border Reproductive Care. The safety of patients, gamete donors, surrogates and future children take centre stage in ESHRE's Good Practice Guide for Cross Border Reproductive Care.
Verizon Communications, Inc. announced Thursday "it will record a related $970 million non-cash charge in the first quarter," The Associated Press reports. "So far at least 15 companies have disclosed about $2.8 billion in charges prompted by the health care overhaul. Verizon's charge is the second-largest after AT&T, which last week announced a $1 billion charge related to the tax bill. Verizon and other companies currently receive a government subsidy to keep prescription drug benefits for retirees.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
James Cook University's (JCU) Papua New Guinea and Pacific Research Forum from the Pacific Island Nations will be discussing the issues affecting the region at Cairns in far north Queensland today. Academics as well as policy makers are likely to convene at the forum.
Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.
› Verified 7 days ago
| Entity Name | Florida Emergency Physicians Kang And Associates Md Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811983752 PECOS PAC ID: 0143113878 Enrollment ID: O20040205000687 |
News Archive
The European Society of Human Reproduction and Embryology is setting the first ever standards in Cross Border Reproductive Care. The safety of patients, gamete donors, surrogates and future children take centre stage in ESHRE's Good Practice Guide for Cross Border Reproductive Care.
Verizon Communications, Inc. announced Thursday "it will record a related $970 million non-cash charge in the first quarter," The Associated Press reports. "So far at least 15 companies have disclosed about $2.8 billion in charges prompted by the health care overhaul. Verizon's charge is the second-largest after AT&T, which last week announced a $1 billion charge related to the tax bill. Verizon and other companies currently receive a government subsidy to keep prescription drug benefits for retirees.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
James Cook University's (JCU) Papua New Guinea and Pacific Research Forum from the Pacific Island Nations will be discussing the issues affecting the region at Cairns in far north Queensland today. Academics as well as policy makers are likely to convene at the forum.
Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.
› Verified 7 days ago
| Entity Name | Emergency Physicians Of St Petersburg Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851726566 PECOS PAC ID: 1658433883 Enrollment ID: O20131018001465 |
News Archive
The European Society of Human Reproduction and Embryology is setting the first ever standards in Cross Border Reproductive Care. The safety of patients, gamete donors, surrogates and future children take centre stage in ESHRE's Good Practice Guide for Cross Border Reproductive Care.
Verizon Communications, Inc. announced Thursday "it will record a related $970 million non-cash charge in the first quarter," The Associated Press reports. "So far at least 15 companies have disclosed about $2.8 billion in charges prompted by the health care overhaul. Verizon's charge is the second-largest after AT&T, which last week announced a $1 billion charge related to the tax bill. Verizon and other companies currently receive a government subsidy to keep prescription drug benefits for retirees.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
James Cook University's (JCU) Papua New Guinea and Pacific Research Forum from the Pacific Island Nations will be discussing the issues affecting the region at Cairns in far north Queensland today. Academics as well as policy makers are likely to convene at the forum.
Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.
› Verified 7 days ago
| Entity Name | Emergency Physicians Of Pinellas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023590056 PECOS PAC ID: 6608128038 Enrollment ID: O20181011002068 |
News Archive
The European Society of Human Reproduction and Embryology is setting the first ever standards in Cross Border Reproductive Care. The safety of patients, gamete donors, surrogates and future children take centre stage in ESHRE's Good Practice Guide for Cross Border Reproductive Care.
Verizon Communications, Inc. announced Thursday "it will record a related $970 million non-cash charge in the first quarter," The Associated Press reports. "So far at least 15 companies have disclosed about $2.8 billion in charges prompted by the health care overhaul. Verizon's charge is the second-largest after AT&T, which last week announced a $1 billion charge related to the tax bill. Verizon and other companies currently receive a government subsidy to keep prescription drug benefits for retirees.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
James Cook University's (JCU) Papua New Guinea and Pacific Research Forum from the Pacific Island Nations will be discussing the issues affecting the region at Cairns in far north Queensland today. Academics as well as policy makers are likely to convene at the forum.
Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.
› Verified 7 days ago
| Entity Name | Emergency Physicians Of Crossroads |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538858774 PECOS PAC ID: 2264894245 Enrollment ID: O20230809000692 |
News Archive
The European Society of Human Reproduction and Embryology is setting the first ever standards in Cross Border Reproductive Care. The safety of patients, gamete donors, surrogates and future children take centre stage in ESHRE's Good Practice Guide for Cross Border Reproductive Care.
Verizon Communications, Inc. announced Thursday "it will record a related $970 million non-cash charge in the first quarter," The Associated Press reports. "So far at least 15 companies have disclosed about $2.8 billion in charges prompted by the health care overhaul. Verizon's charge is the second-largest after AT&T, which last week announced a $1 billion charge related to the tax bill. Verizon and other companies currently receive a government subsidy to keep prescription drug benefits for retirees.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
James Cook University's (JCU) Papua New Guinea and Pacific Research Forum from the Pacific Island Nations will be discussing the issues affecting the region at Cairns in far north Queensland today. Academics as well as policy makers are likely to convene at the forum.
Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nicholas Paul Marburger, DO 5870 Hiatus Rd, Tamarac, FL 33321-6424 Ph: () - | Dr Nicholas Paul Marburger, DO 601 E Rollins St, Orlando, FL 32803-1248 Ph: (407) 303-5600 |
News Archive
The European Society of Human Reproduction and Embryology is setting the first ever standards in Cross Border Reproductive Care. The safety of patients, gamete donors, surrogates and future children take centre stage in ESHRE's Good Practice Guide for Cross Border Reproductive Care.
Verizon Communications, Inc. announced Thursday "it will record a related $970 million non-cash charge in the first quarter," The Associated Press reports. "So far at least 15 companies have disclosed about $2.8 billion in charges prompted by the health care overhaul. Verizon's charge is the second-largest after AT&T, which last week announced a $1 billion charge related to the tax bill. Verizon and other companies currently receive a government subsidy to keep prescription drug benefits for retirees.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
James Cook University's (JCU) Papua New Guinea and Pacific Research Forum from the Pacific Island Nations will be discussing the issues affecting the region at Cairns in far north Queensland today. Academics as well as policy makers are likely to convene at the forum.
Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.
› Verified 7 days ago
Landon Lichtman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 E Rollins St, Orlando, FL 32803 Phone: 407-303-1940 | |
Dr. Julian Andrew Trivino, D.O., M.S. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7727 Lake Underhill Rd, Orlando, FL 32822 Phone: 407-303-6413 | |
Ramon H Nunez, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 E Rollins St, Orlando, FL 32803 Phone: 407-303-5600 | |
Dr. Steve Wahel Hilwa, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 86 W Underwood St, Suite 200, Orlando, FL 32806 Phone: 407-237-6329 Fax: 407-649-3083 | |
Dr. Kenneth Vernon Slack, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7727 Lake Underhill Rd, Orlando, FL 32822 Phone: 407-303-6413 | |
Dr. Hunter Kane Steward, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 52 W Underwood St # Mp31, Orlando, FL 32806 Phone: 321-841-5111 | |
Marc Santambrosio, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 E Rollins St, Orlando, FL 32803 Phone: 407-303-5600 |